APGE

APGE

USD

Apogee Therapeutics Inc. Common Stock

$54.710-0.290 (-0.527%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$55.000

High

$55.930

Low

$52.340

Volume

1.04M

Company Fundamentals

Market Cap

3.7B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.66M

Exchange

NGM

Currency

USD

52-Week Range

Low $26.2Current $54.710High $63.5

Related News

GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026,

View more
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109

Craig-Hallum analyst Adam Vogel initiates coverage on Apogee Therapeutics with a Buy rating and announces Price Target of $109.

View more
Craig-Hallum Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $109
Analyst Upgrades

RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics with a Outperform and raises the price target from $60 to $70.

View more
RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70
GlobeNewswire

Apogee Therapeutics to Participate in Upcoming Conferences

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd

View more
Apogee Therapeutics to Participate in Upcoming Conferences
Analyst Upgrades

Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105

Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics with a Outperform rating and announces Price Target of $105.

View more
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105